Revelation Biosciences, Inc. (REVB) investor relations documents from the company's IR site: 1 presentation, 5 press releases; latest deck 2026-06-09. Read in-app with summaries. First-party data.
Presentation: Revelation Biosciences is developing Gemini, a PHAD-based therapeutic targeting acute kidney injury, with a $5 billion market opportunity and a pivotal study planned.
| Published | Type | Document |
|---|---|---|
| 2026-08-06 | Press release | Revelation Biosciences, Inc. Announces Financial Results For the Three and Six Months Ended June 30, 2026 |
| 2026-06-09 | Presentation | Presentation |
| 2026-05-07 | Press release | Press release |
| 2026-02-26 | Press release | Press release |
| 2026-01-26 | Press release | Press release |
| 2025-12-01 | Press release | Revelation Biosciences Has Reached A Quorum For Its December 3, 2025 Special Meeting |
REVB overview · REVB earnings · REVB financials · REVB KPIs · REVB ownership · REVB peers · REVB filings
Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.